Optimizing therapeutic strategies in advanced bladder cancer : Update on chemotherapy and the role of targeted agentsBELLMUNT, J; ALBIOL, S; SUAREZ, C et al.Critical reviews in oncology/hematology. 2009, Vol 69, Num 3, pp 211-222, issn 1040-8428, 12 p.Article

The ErbB receptors as targets for breast cancer therapyALBANELL, J; BASELGA, J.Journal of mammary gland biology and neoplasia. 1999, Vol 4, Num 4, pp 337-351, issn 1083-3021Article

A feasibility study of carboplatin with fixed dose of gemcitabine in 'unfit' patients with advanced bladder cancerBELLMUNT, J; DE WIT, R; ALBANELL, J et al.European journal of cancer (1990). 2001, Vol 37, Num 17, pp 2212-2215, issn 0959-8049Article

Prostate cancer Multidisciplinary approach : a key to successMONTAGUT, C; ALBANELL, J; BELLMUNT, J et al.Critical reviews in oncology/hematology. 2008, Vol 68, issn 1040-8428, S32-S36, SUP1Conference Paper

A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter studyALBA, E; CHACON, J. I; ALVAREZ, R et al.Breast cancer research and treatment. 2012, Vol 136, Num 2, pp 487-493, issn 0167-6806, 7 p.Article

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancerALBANELL, J; GONZALEZ, A; BERMEJO, B et al.Annals of oncology. 2012, Vol 23, Num 3, pp 625-631, issn 0923-7534, 7 p.Article

Mechanism of action of anti-HER2 monoclonal antibodiesBASELGA, J; ALBANELL, J.Annals of oncology. 2001, Vol 12, pp 35-41, issn 0923-7534, SUP1Conference Paper

Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urotheliumBELLMUNT, J; GUILLEM, V; BASTUS, R et al.Journal of clinical oncology. 2000, Vol 18, Num 18, pp 3247-3255, issn 0732-183XArticle

Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancerBELLMUNT, J; GUILLEM, V; PAZ-ARES, L et al.European journal of cancer. Supplement (1990). 2000, Vol 36, Num 2, pp S17-S25, issn 1359-6349Article

Predicting response and survival in chemotherapy-treated triple-negative breast cancerPRAT, A; LLUCH, A; SEGUI-PALMER, M. A et al.British journal of cancer. 2014, Vol 111, Num 8, pp 1532-1541, issn 0007-0920, 10 p.Article

Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancerROJO, F; GARCIA-PARRA, J; LOBO, F et al.Annals of oncology. 2012, Vol 23, Num 5, pp 1156-1164, issn 0923-7534, 9 p.Article

DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancerMONCHO-AMOR, V; IBANEZ DE CACERES, I; ROJO, F et al.Oncogene (Basingstoke). 2011, Vol 30, Num 6, pp 668-678, issn 0950-9232, 11 p.Article

Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer : a phase 1/11 dose-escalation studyAWADA, A; ALBANELL, J; CANNEY, P. A et al.British journal of cancer. 2008, Vol 98, Num 9, pp 1500-1507, issn 0007-0920, 8 p.Article

Proliferation Signal Inhibitors in Transplantation : Questions at the Cutting Edge of Everolimus TherapyCHAPMAN, J. R; VALANTINE, H; NASHAN, B et al.Transplantation proceedings. 2007, Vol 39, Num 10, pp 2937-2950, issn 0041-1345, 14 p.Article

New drugs and new approaches in metastatic bladder cancerBELLMUNT, J; DE WIT, R; ALBIOL, S et al.Critical reviews in oncology/hematology. 2003, Vol 47, Num 2, pp 195-206, issn 1040-8428, 12 p.Article

High telomerase activity in Primary lung cancers : Association with increased cell proliferation rates and advanced pathologic stageALBANELL, J; LONARDO, F; RUSCH, V et al.Journal of the National Cancer Institute. 1997, Vol 89, Num 21, pp 1609-1615, issn 0027-8874Article

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II studyALBA, E; CALVO, L; CARRASCO, E et al.Annals of oncology. 2012, Vol 23, Num 12, pp 3069-3074, issn 0923-7534, 6 p.Article

MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell linesARRIOLA, E; CANADAS, I; SERRANO, S et al.British journal of cancer. 2011, Vol 105, Num 6, pp 814-823, issn 0007-0920, 10 p.Article

Systemic therapy emergenciesALBANELL, J; BASELGA, J.Seminars in oncology. 2000, Vol 27, Num 3, pp 347-361, issn 0093-7754Article

Recombinant humanized anti-HER2 antibody (herceptin^TM) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenograftsBASELGA, J; NORTON, L; ALBANELL, J et al.Cancer research (Baltimore). 1998, Vol 58, Num 13, pp 2825-2831, issn 0008-5472Article

Relative contribution of normal and neoplastic cells determines telomerase activity and telomere length in primary cancers of the prostate, colon, and sarcomaENGELHARDT, M; ALBANELL, J; DRULLINSKY, P et al.Clinical cancer research. 1997, Vol 3, Num 10, pp 1849-1857, issn 1078-0432Article

Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cellsENGELHARDT, M; KUMAR, R; ALBANELL, J et al.Blood. 1997, Vol 90, Num 1, pp 182-193, issn 0006-4971Article

Frequent dose delays and growth factor requirements with the sequential doxorubicin-CMF scheduleRIBAS, A; ALBANELL, J; BELLMUNT, J et al.Acta oncologica (Stockholm). 1997, Vol 36, Num 7, pp 701-704, issn 0284-186XArticle

Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensityRIBAS, A; ALBANELL, J; BASELGA, J et al.Journal of clinical oncology. 1996, Vol 14, Num 5, pp 1573-1580, issn 0732-183XArticle

A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancerTABERNERO, J; CLIMENT, M. A; LOSA, I et al.Annals of oncology. 2004, Vol 15, Num 9, pp 1358-1365, issn 0923-7534, 8 p.Article